# Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

> **NCT00211523** · PHASE2 · COMPLETED · sponsor: **BioWest Therapeutics Inc** · enrollment: 75 (—)

## Conditions studied

- Acne Vulgaris
- Acne
- Propionibacterium Acnes

## Interventions

- **DRUG:** MBI 226 Acne Solutions

## Key facts

- **NCT ID:** NCT00211523
- **Lead sponsor:** BioWest Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** —
- **Final completion:** 2001-09
- **Target enrollment:** 75 (—)
- **Last updated:** 2005-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211523, "Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00211523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*